

Sexual Dysfunction Drugs 2017 Global Market Expected to Grow at CAGR Of 2.79% and Forecast to 2021

Wiseguyreports.Com Publish New Market Research Report On-"Sexual Dysfunction Drugs 2017 Global Market Expected to Grow at CAGR Of 2.79% and Forecast to 2021".

PUNE, INDIA, September 11, 2017 /EINPresswire.com/ --

Sexual Dysfunction Drugs Market 2017

Executive Summary

Sexual dysfunctions include sexual disorders of men and women that can interfere with their sexual performance, leading to unsatisfied sexual intercourse. The major drugs used in this market are PDE5 inhibitors, whereas other drugs such as hormone-related and transurethral also have a presence in the market. Erectile dysfunction (ED) is a highly prevalent sexual dysfunction seen in men.



Globally, there has been an increase in the number of ED cases caused due to high blood pressure, obesity, neurological and nerve disorders, prostate cancer, and diabetes among others.

The analysts forecast the global sexual dysfunction drugs market to grow at a CAGR of 2.79% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global sexual dysfunction drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

Request a Sample Report @ <u>https://www.wiseguyreports.com/sample-request/2176189-global-sexual-dysfunction-drugs-market-2017-2021</u>

The report, Global Sexual Dysfunction Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

- AbbVie
- Bayer
- Eli Lilly
- Pfizer

Other prominent vendors

- Apricus Biosciences
- Emotional Brain
- GlaxoSmithKline
- Ivix LLX
- Leadiant Biosciences
- Merck
- NexMed
- Palatin Technologies and PRA Health Sciences
- S1 Biopharma
- Takeda
- Teva Pharmaceutical Industries
- Trimel Biopharma SRL
- Vietstar Biomedical Research

Market driver

- Rising prevalence of sexual dysfunctions
- For a full, detailed list, view our report

Market challenge

- Technological advancements, a threat to drug therapy
- For a full, detailed list, view our report

Market trend

- Increased focus on generic drugs
- For a full, detailed list, view our report

Key questions answered in this report

- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?

Complete Report Details @ <u>https://www.wiseguyreports.com/reports/2176189-global-sexual-</u> <u>dysfunction-drugs-market-2017-2021</u>

Table of Contents -Analysis of Key Points

PART 01: Executive summary

- PART 02: Scope of the report
- PART 03: Research Methodology
- PART 04: Introduction
- Market outline

PART 05: Disease overview

- Sexual dysfunction: Definition
- Causes of sexual dysfunction

PART 06: Market landscape

- Market overview
- Market size and forecast
- Five forces analysis

PART 07: Pipeline PART 08: Market segmentation by therapy

- Oral therapy
- Intracavernosal therapy
- Hormonal therapy
- Transurethral therapy

PART 09: Geographical segmentation

- Sexual dysfunction drugs market in Americas
- Sexual dysfunction drugs market in EMEA

• Sexual dysfunction drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

- Market drivers
- Market challenges

PART 12: Market trends

- Increased focus on generic drugs
- Migration of manufacturing and sales facilities to APAC
- Advancing biomedical science

.....Continued

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2176189

Norah Trent wiseguyreports +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/403165549

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2021 IPD Group, Inc. All Right Reserved.